These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20017910)

  • 81. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
    Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P
    J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.
    Lee SH; Park S; Kang SM; Jang Y; Chung N; Choi D
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):65-71. PubMed ID: 21386036
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
    Lee CW; Baek SH; Hong TJ; Choi YJ; Kim YJ; Ahn TH; Ihm SH; Bae JH; Hong SJ; Kim DI; Ahn YK; Hur SH; Park DG; Choi DJ; Lee SU; Kim BS; Ryu KH; Jang YS; Lee SH; Seung KB; Kim HS
    Cardiovasc Drugs Ther; 2010 Apr; 24(2):181-8. PubMed ID: 20383571
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
    Branchi A; Fiorenza AM; Torri A; Muzio F; Berra C; Colombo E; Dalla Valle E; Rovellini A; Sommariva D
    Clin Ther; 2001 Jun; 23(6):851-7. PubMed ID: 11440285
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I; Salomon H; Després JP
    Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
    Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
    Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Liptruzet: a combination of ezetimibe and atorvastatin.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):49-50. PubMed ID: 23797796
    [No Abstract]   [Full Text] [Related]  

  • 92. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
    Ooi TC; Heinonen T; Alaupovic P; Davignon J; Leiter L; Lupien PJ; Sniderman AD; Tan MH; Tremblay G; Sorisky A; Shurzinske L; Black DM
    Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1793-9. PubMed ID: 9327779
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
    Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
    Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
    Gagné C; Bays HE; Weiss SR; Mata P; Quinto K; Melino M; Cho M; Musliner TA; Gumbiner B;
    Am J Cardiol; 2002 Nov; 90(10):1084-91. PubMed ID: 12423708
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
    Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A
    Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
    Bays H; Conard S; Leiter LA; Bird S; Jensen E; Hanson ME; Shah A; Tershakovec AM
    Lipids Health Dis; 2010 Nov; 9():136. PubMed ID: 21118495
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study).
    Kanat M; Serin E; Tunckale A; Yildiz O; Sahin S; Bolayirli M; Arinc H; Dirican A; Karagoz Y; Altuntas Y; Celebi H; Oguz A
    J Endocrinol Invest; 2009 Nov; 32(10):852-6. PubMed ID: 19783896
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study.
    Oikawa S; Yamashita S; Nakaya N; Sasaki J; Kono S;
    J Atheroscler Thromb; 2017 Jan; 24(1):77-94. PubMed ID: 27397061
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
    Insull W; Toth PP; Superko HR; Thakkar RB; Krause S; Jiang P; Parreno RA; Padley RJ
    Vasc Health Risk Manag; 2010 Nov; 6():1065-75. PubMed ID: 21191426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.